IVVD in the 13F filings
Adagio Therapeutics Inc · CUSIP 00534A102
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 18 May 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 20
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 3 listed it in both
- Shares listed
- 69,364,238
- combined, among listed positions
- Reported value
- $90m
- combined, at the quarter end
1 line marked †. Value as filed implies a price far from other filers'. Each counts in holders and value as filed, and is left out of the net change in shares.
Among the 91 comparable managers: 14 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -9,340,155.
Managers listing IVVD in Q1 2026
20 of 20 holders
Largest increases and reductions, by shares
Increases
- Millennium Management LLCexisting position · 3,511,581 shares now+2,225,126
- Susquehanna International Group LLPexisting position · 1,903,713 shares now+1,277,930
- Citadel Advisors LLCexisting position · 1,589,575 shares now+1,258,492
- Marshall Wace LLPnew position · 1,226,165 shares now+1,226,165
- Squarepoint Ops LLCexisting position · 819,968 shares now+615,377
Reductions
- Point72 Asset Management LPexisting position · 43,931 shares now-16,609,105
- Balyasny Asset Management LLCexisting position · 3,515,644 shares now-291,332
- Two Sigma Investments LPexisting position · 1,969,659 shares now-222,241
- Renaissance Technologies LLCexisting position · 846,265 shares now-180,355
- Fidelity (FMR LLC)existing position · 141,270 shares now-669
New positions and exits
New (5)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2021 | 3 | $670m | n.a. | n.a. |
| Q1 2022 | 1 | $4.5m | n.a. | n.a. |
| Q1 2023 | 1 | $2.3m | n.a. | n.a. |
| Q2 2023 | 1 | $2.5m | n.a. | n.a. |
| Q3 2023 | 1 | $9.0m | n.a. | n.a. |
| Q4 2023 | 1 | $37m | 1 | 0 |
| Q1 2024 | 1 | $52m | 1 | 0 |
| Q2 2024 | 1 | $13m | 0 | 0 |
| Q3 2024 | 1 | $12m | 0 | 0 |
| Q4 2024 | 1 | $5.2m | 0 | 0 |
| Q1 2025 | 1 | $6.6m | 0 | 1 |
| Q2 2025 | 1 | $7.3m | 0 | 1 |
| Q3 2025 | 1 | $21m | 1 | 0 |
| Q4 2025 | 3 | $169m | 11 | 5 |
| Q1 2026 | 2 | $68m | 14 | 5 |
| Q2 2026 | 1 | $17m | 9 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IVVD and GILD →IVVD and AMGN →IVVD and ARGX →Choose a stock to compare with IVVD →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IVVD, latest filings →Back to the 13F Explorer →